X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results
X4 Pharmaceuticals announced its financial results for the third quarter ended September 30, 2026, reporting a net loss of $20.2 million and providing updates on its clinical trials.
Stocks · News reference
The U.S. Food and Drug Administration has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
X4 Pharmaceuticals announced its financial results for the third quarter ended September 30, 2026, reporting a net loss of $20.2 million and providing updates on its clinical trials.
X4 Pharmaceuticals announced its participation in three upcoming healthcare investor conferences scheduled for November 2026.
During its 2026 Virtual Investor Day, X4 Pharmaceuticals provided updates on its clinical programs, including the expected completion of 4WARD trial enrollment and market projections for mavorixafor in primary chronic neutropenia.
Filed: 2026-10-29 AccNo: 0001501697-26-000084 Size: 4 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits